NASDAQ · HCWB
Healthcare · Biotechnology
$2.01
Down-$0.04 (-1.95%)
Updated Sep 17, 2026, 5:59 AM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
HCWB closed at $2.01 after 20 trading sessions, down 12.61% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $2.09 | $2.10 | $1.89 | $2.01 | 86.47K |
| Sep 15, 2026 | $2.17 | $2.1891 | $2.05 | $2.05 | 55.47K |
| Sep 14, 2026 | $2.2401 | $2.325 | $2.18 | $2.20 | 100.02K |
| Sep 11, 2026 | $2.43 | $2.445 | $2.16 | $2.24 | 94.71K |
| Sep 10, 2026 | $2.42 | $2.52 | $2.41 | $2.43 | 31.76K |
| Sep 9, 2026 | $2.44 | $2.53 | $2.34 | $2.46 | 102.29K |
| Sep 8, 2026 | $2.52 | $2.72 | $2.10 | $2.51 | 3.09M |
| Sep 4, 2026 | $2.81 | $2.97 | $2.80 | $2.94 | 37.3K |
| Sep 3, 2026 | $3.34 | $3.34 | $2.7001 | $2.87 | 127.59K |
| Sep 2, 2026 | $3.54 | $3.81 | $3.32 | $3.355 | 210.75K |
| Sep 1, 2026 | $3.51 | $3.73 | $3.30 | $3.45 | 545.88K |
| Aug 31, 2026 | $3.60 | $3.60 | $3.2105 | $3.59 | 59.02K |
| Aug 28, 2026 | $3.20 | $3.43 | $3.00 | $3.43 | 127.56K |
| Aug 27, 2026 | $2.70 | $3.28 | $2.60 | $3.17 | 337.62K |
| Aug 26, 2026 | $2.69 | $2.70 | $2.55 | $2.70 | 62.39K |
| Aug 25, 2026 | $2.31 | $2.8881 | $2.28 | $2.60 | 281.82K |
| Aug 24, 2026 | $2.32 | $2.3233 | $2.15 | $2.31 | 308.04K |
| Aug 21, 2026 | $2.16 | $2.23 | $2.05 | $2.18 | 55.86K |
| Aug 20, 2026 | $2.26 | $2.38 | $2.06 | $2.12 | 90.09K |
| Aug 19, 2026 | $2.14 | $2.3999 | $2.13 | $2.30 | 111.86K |
The latest Smart Investors Daily articles mentioning HCWB.
HCWB research
Company profile and research snapshot.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 28, 2026 | Maxim Group | Buy | — |
| May 29, 2025 | Maxim Group | Buy | — |
| Apr 19, 2023 | EF Hutton | Buy | — |
| Mar 30, 2023 | EF Hutton | Buy | — |
| Mar 23, 2023 | EF Hutton | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 8, 2026
HCW Biologics Inc. (NASDAQ:HCWB) has entered into an exclusive distribution agreement with Akron Biotech covering HCW11-006, its multi-cytokine fusion molecule designed for use as a reagent in CAR-T cell manufacturing.
Yahoo · Sep 8, 2026
Agreement includes pre-payment commitments for product sales and distribution of the second-generation multi-cytokine-based HCW11-006 for use as a reagent Akron is a leading supplier of critical ancillary materials and accessory molecules for clinical and commercial scale-up of cell, gene and regenerative therapy products HCW Biologics supplies research and cGMP-grade HCW11-006 and Akron markets and distributes the reagent to its established network of research institutions and commercial compan
Benzinga · Sep 8, 2026
HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapeutics to treat autoimmune
Yahoo · Sep 2, 2026
HCW9302 is a best-in-class IL-2-based immunotherapeutic for treatment of autoimmune diseases through expanding and activating regulatory T cells Patent allowance received for use of HCW9302 as treatment for alopecia areata Phase 1 dose-escalating clinical study evaluating HCW9302 as monotherapy in patients with alopecia areata on track for completion in Q4 2026, continues to be well tolerated with no dose-limiting toxicities Preliminary readout of first two dose cohorts is encouraging -- patient
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning HCWB.
